Literature DB >> 9927163

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

P Chariot1, I Drogou, I de Lacroix-Szmania, M C Eliezer-Vanerot, B Chazaud, A Lombès, A Schaeffer, E S Zafrani.   

Abstract

Zidovudine is known to be responsible for a mitochondrial myopathy with ragged-red fibres and mitochondrial DNA depletion in muscle. Lactic acidosis alone or associated with hepatic abnormalities has also been reported. A single report mentioned the concomitant occurrence of muscular and hepatic disturbances and lactic acidosis in a patient receiving zidovudine, but muscle and liver tissues were not studied. A 57-year-old man with AIDS, who had been treated with zidovudine for 3 years, developed fatigue and weight loss. Serum creatine kinase and hepatic enzyme levels were high. Lactic acidosis was present. Liver biopsy showed diffuse macrovacuolar and microvacuolar steatosis. After withdrawal of zidovudine, creatine kinase, aspartate aminotransferase, and alanine aminotransferase levels normalised within 5 days, and lactacidaemia decreased. Acidosis persisted. The patient became confused and febrile and died 8 days after detection of high blood lactic acid. A muscle sample obtained at autopsy showed mitochondrial abnormalities with ragged-red fibres and lipid droplet accumulation. Southern blot analysis showed depletion of mitochondrial DNA, affecting skeletal muscle and liver tissue. No depletion was found in myocardium and kidney. This case emphasises that zidovudine treatment can induce mitochondrial multisystem disease, as revealed in our case by myopathy, liver steatosis and lactic acidosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927163     DOI: 10.1016/s0168-8278(99)80020-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

1.  Impaired redox status and cytochrome c oxidase deficiency in patients with polymyalgia rheumatica.

Authors:  P Chariot; X Chevalier; M Yerroum; I Drogou; F J Authier; R Gherardi
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Hyperlactatemia and human immunodeficiency virus infection: lessons from the era of antiretroviral monotherapy.

Authors:  Patrick Chariot; Nacer Bourokba; Isabelle Monnet; Romain Gherardi
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart.

Authors:  Delia Susan-Resiga; Alice T Bentley; Matthew D Lynx; Darcy D LaClair; Edward E McKee
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria.

Authors:  Matthew D Lynx; Edward E McKee
Journal:  Biochem Pharmacol       Date:  2006-04-25       Impact factor: 5.858

Review 5.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

6.  Repeat lactate level predicts mortality better than rate of clearance.

Authors:  Zachary D W Dezman; Angela C Comer; Gordon S Smith; Peter F Hu; Colin F Mackenzie; Thomas M Scalea; Jon Mark Hirshon
Journal:  Am J Emerg Med       Date:  2018-03-07       Impact factor: 2.469

Review 7.  Drug-induced steatohepatitis.

Authors:  Vaishali Patel; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

Review 8.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

Review 9.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

10.  Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.

Authors:  Bernhard Setzer; Dirk Lebrecht; Ulrich A Walker
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.